Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
about
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewFenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experienceReversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.The pros and the cons of mTOR inhibitors in kidney transplantation.Diabetes and other endocrine-metabolic abnormalities in the long-term follow-up of pancreas transplantation.Renal failure (chronic)Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.False estimates of elevated creatinine.Metabolic syndrome and chronic kidney disease: Current status and future directions.Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.Consensus statement on management of dyslipidemia in Indian subjects.An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.Fibrates: what have we learned in the past 40 years?Antioxidant and Hypolipidemic Activity of the Hydroethanolic Extract of Curatella americana L. Leaves.Management of dyslipidemia in patients after solid organ transplantation.Kidney function and estimated vascular risk in patients with primary dyslipidemiaGemfibrozil, stretching arms beyond lipid lowering.Gout and organ transplantation.Fenofibrate and the kidney: an overview.Role of dyslipidemia in patients with chronic kidney disease.Effect of Fenofibrate Medication on Renal Function.Fibrate treatment can increase serum creatinine levels.Fibrate-induced increase in blood urea and creatinine.Fibrate-induced increase in serum urea and creatinine levels.Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy.Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes.A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
P2860
Q26747559-1897A9DE-3820-4549-9C0B-81BF580F9D34Q28220294-C756CE87-3F2A-4B0B-9BEB-E490F7DB47DCQ30419020-87D85B50-4697-47F9-B4C9-97337554B76FQ30419512-1ED49F35-4E3C-4E3C-9307-508189680DFCQ33412367-3C293197-FC94-4F2A-BDBA-CCCF620079CDQ33802182-47F1F979-EF06-4680-8D26-3BDC7CEA8F53Q33910618-7A4E30AC-A404-4BC4-AF4C-96343ABC47DFQ34068746-A9B4A834-B300-46D5-8F04-93D70C5376B8Q34284957-8A4E1660-A3FB-4478-8A85-06DD43E5810BQ34453266-78DB9103-2235-49FE-9D40-B777E9B541A7Q34695851-E77F8F56-DD4C-4137-A478-5C07ECAF5E8CQ34980772-93779F78-A22B-41C5-BF46-7FFF7D6155E4Q35569823-6BCBB7C2-CF3B-4003-8C9E-E3976E17C6B4Q35684825-B7F2B4A8-CBF2-413F-A746-0492D9EC5149Q36013120-07FCD5C9-C095-4384-AACA-D3C66A934CA5Q36742410-CC93768C-CF1C-41FE-8A53-E41A2746BCDDQ36924863-CD3FB855-3327-462D-89F7-A30F4080DE71Q37158327-6CF79237-98ED-47ED-AD48-BDADE6BF4CB5Q37245464-5A210100-89A4-486C-B1F3-386CD382B67FQ37411250-235F6507-C82E-4842-BDE8-8260F96E40B2Q37976996-65E5B3EA-9CF0-4299-B7B9-0817D489A0CBQ38088377-D87D9DDC-D603-4B2D-8D41-3F1FE9ADFBB5Q38120646-D98BB9F4-B80A-431B-8422-AE1551480F39Q41223740-B3C8402B-9A03-4B5D-8D26-C4E172A3F042Q43629105-4E9BA705-6CEE-4CCF-9EDE-67FFE872FA88Q43654556-DF070BE2-64AF-40AF-B484-2552C7247F37Q43935636-02F3E12A-7DBD-4B18-B833-ED8121BF9196Q44255217-003263A3-8CEF-4D1E-A71B-22ABCDB011BFQ44258250-B03474D8-EFAB-445B-A7BE-594BC012ABCDQ44344284-EE28E886-A78E-4891-8BAA-6D70DF53600DQ44803518-A219F8C0-66DF-4EEC-ADED-B71EE6D5860AQ46973476-086CC39A-205C-4116-8176-2C21C356E3F4Q46973482-F4003B2D-296A-4789-9CDF-AE2225F78559
P2860
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@ast
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@en
type
label
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@ast
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@en
prefLabel
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@ast
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@en
P2093
P356
P1476
Fibrate-induced increase in bl ...... ozil the only innocuous agent?
@en
P2093
Abramowicz D
Broeders N
Tielemans C
P304
P356
10.1093/NDT/15.12.1993
P407
P577
2000-12-01T00:00:00Z